AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia
Shots:
- The P-III CLL14 trial assessing the efficacy & safety of a combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab and chlorambucil in 432 patients with previously untreated CLL
- Results: @median follow-up of 52.4 mos.- PFS rate (74% vs 35.4%) after 1 yr. fixed-duration treatment- 67% reduction in risk of disease progression or death; OS rate (85.4% vs 83.1%)- no new safety signals were identified- improvement in PFS was observed in all clinical & biological risk groups- includes TP53 mutation- 17p deletion & unmutated IGHV status
- Additionally- 26.9% of patients with Venclyxto/Venclexta-based combination still had undetectable MRD compared to 3.2% of patients with obinutuzumab + chlorambucil arm @ 30 mos.
| Ref: Abbvie | Image:abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com